21
SEP
2016
NW Bio Presents Updated Data From DCVax®-Direct Phase I Trial At 5th Annual SMi Cancer Vaccines Conference in London
Comments : Off
Dr. Marnix Bosch, Chief Technical Officer, Presented BETHESDA, MD, September 21, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, Chief Technical Officer, today presented an updated and more detailed analysis of the Phase I DCVax®-Direct Trial data at the 5th Annual SMi Cancer Vaccines... Read More